GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Quality Rank

Sinocelltech Group (SHSE:688520) Quality Rank


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Sinocelltech Group Quality Rank Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocelltech Group (SHSE:688520) Business Description

Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Executives
Xie Liang Zhi Director